Results 61 to 70 of about 7,229 (203)
, 2011 Background Rilpivirine and efavirenz share metabolic pathways (CYP3A), potentially leading to drug–drug interactions. We report the pharmacokinetics, ex vivo antiviral activity and safety of rilpivirine, following efavirenz treatment.
James Witek +4 more
core +1 more source
Virtual Screening of candidate Bio-actives from selected medicinal plants against rilpivirine resistance in HIV [PDF]
E3S Web of ConferencesHIV, the causative virus of AIDS, has posed a severe threat to global health for an extensiveperiod. Recent statistics show the magnitude of this challenge, with approximately 2.4 million people inIndia living with HIV, along with 41.97 thousand deaths ...
Kumar Anish +4 more
doaj +1 more source
Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.Multi‐endpoint clinical trials face long‐standing statistical challenges. Vector‐based comparison (VBC) decomposes endpoints into orthogonal components. Applied to five clinical trials, it reduced confidence‐interval widths by about 50%, indicating higher statistical power, without altering the clinical meaning of endpoints.
Maria Kokkali, Vangelis D. Karalis
wiley +1 more source
HIV/AIDS: Research and Palliative Care, 2013 Opass Putcharoen,1–3 Stephen J Kerr,4 Kiat Ruxrungtham2,4,5 1Division of Infectious Diseases, Department of Medicine, Chulalongkorn University, 2Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn ...
Putcharoen O, Kerr SJ, Ruxrungtham K
doaj
Viruses, 2014 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs.
Nicolas Sluis-Cremer
doaj +1 more source
Background Long-acting injectable cabotegravir and rilpivirine (LAI cabotegravir and rilpivirine) is recommended as maintenance therapy for people living with HIV who achieved viral suppression on oral antiretroviral therapy (ART). However, its effect on
Loosli, Tom +10 more
core +2 more sources
Journal of Medical Virology, Volume 98, Issue 8, August 2026.ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca +18 more
wiley +1 more source
HIV Research & Clinical Practice, 2020 Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity.
Valentina Di Cristo +14 more
doaj +1 more source
Medications That Regulate Pregnane X Receptor: A Systematic Review of Current Evidence
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.PRISMA 2020 flow diagram of study selection for this systematic review of medications that regulate the pregnane X receptor (PXR), from 12 236 records screened to 101 included studies. ABSTRACT The pregnane X receptor (PXR) gene encodes a ligand‐activated protein involved with the metabolism and excretion of drugs, toxins, and other xenobiotics.
Petra Czarniak +4 more
wiley +1 more source
, 2023 Background. Long-acting (LA) intramuscular cabotegravir and rilpivirine are prone to drug-drug interactions (DDI). However, given the long dosing interval, the conduct of clinical DDIs studies with LA antiretrovirals is challenging.
Marzolini, C. +9 more
core +1 more source